{"id":"ondansetron-and-dyclonine-hydrochloride","safety":{"commonSideEffects":[{"rate":"9-27%","effect":"Headache"},{"rate":"5-11%","effect":"Constipation"},{"rate":"3-8%","effect":"Diarrhea"},{"rate":"3-7%","effect":"Fatigue"},{"rate":"2-5%","effect":"Dizziness"},{"rate":null,"effect":"Local irritation (from dyclonine)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ondansetron is a selective 5-HT3 receptor antagonist that prevents chemotherapy-induced and postoperative nausea and vomiting by blocking serotonin signaling in the chemoreceptor trigger zone and gastrointestinal tract. Dyclonine hydrochloride is a local anesthetic that numbs mucous membranes. This combination formulation likely targets both the central and peripheral mechanisms of nausea while providing topical anesthetic relief.","oneSentence":"Ondansetron blocks serotonin 5-HT3 receptors to prevent nausea and vomiting, while dyclonine hydrochloride provides local anesthetic action.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:58:25.783Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chemotherapy-induced nausea and vomiting (CINV)"},{"name":"Postoperative nausea and vomiting (PONV)"},{"name":"Radiation-induced nausea and vomiting"}]},"trialDetails":[{"nctId":"NCT07336680","phase":"PHASE4","title":"Effect of Ondansetron on Patient Tolerance, Efficacy and Endoscopist Workload in Unsedated Endoscopy for Upper Gastrointestinal Bleeding","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2026-01-01","conditions":"Esophagogastroduodenoscopy, Upper Gastrointestinal Bleeding (UGIB)","enrollment":80},{"nctId":"NCT07264738","phase":"PHASE4","title":"Oral Ondansetron to Improve Patient Experience of Unsedated Esophagogastroduodenoscopy Pilot Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2025-07-01","conditions":"Esophagogastroduodensocopy (EGD) Procedure","enrollment":40},{"nctId":"NCT06729307","phase":"PHASE4","title":"Ondansetron Combined with Dyclonine Hydrochloride to Improve Patient Experience in Unsedated Esophagogastro-duodenoscopy","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2025-01","conditions":"Esophagogastroduodensocopy (EGD) Procedure","enrollment":260}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"ondansetron and dyclonine hydrochloride","genericName":"ondansetron and dyclonine hydrochloride","companyName":"Peking Union Medical College Hospital","companyId":"peking-union-medical-college-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ondansetron blocks serotonin 5-HT3 receptors to prevent nausea and vomiting, while dyclonine hydrochloride provides local anesthetic action. Used for Chemotherapy-induced nausea and vomiting (CINV), Postoperative nausea and vomiting (PONV), Radiation-induced nausea and vomiting.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}